Ocera Therapeutics Inc news

   Watch this stock
Showing stories 1 - 10 of about 23   

Articles published

OCRX 5.51 -0.03 (-0.54%)
price chart
Ocera Therapeutics Announces Appointment of Steven P. James to Board
Ocera Therapeutics, Inc. OCRX, +0.54% a clinical stage biopharmaceutical company focused on acute and chronic orphan liver diseases, today announced that Steven P. James has been appointed to the Company's Board of Directors.
Ocera Therapeutics Inc.: Ocera Therapeutics Announces Appointment of Steven ...  The Wall Street Transcript
Related articles »  
Why You Shouldn't Bet Against Ocera Therapeutics (OCRX) Stock - Tale of the ...
One stock that might be an intriguing choice for investors right now is Ocera Therapeutics, Inc. ( OCRX ). This is because this security in the Med-Biomed/Generic industry space is seeing solid earnings estimate revision activity, and is in great ...
Related articles »  
Today's Watch List: Amicus Therapeutics (NASDAQ:FOLD), Ocera Therapeutics ...
Amicus Therapeutics, Inc. (NASDAQ:FOLD) was a big mover last session with its shares rising over 10% on the day. The move came on solid volume too with far more shares changing hands than in a normal session.
Related articles »  
Stock Runners : Ciena Corporation (NYSE:CIEN), Ocera Therapeutics (NASDAQ ...
On AUG 11, Ocera Therapeutics, Inc. (NASDAQ:OCRX), a clinical stage biopharmaceutical company focused on acute and chronic orphan liver diseases, announced that Rajiv Patni, M.D.
Worth Watching Stocks: TrovaGene (NASDAQ:TROV), Ocera Therapeutics ...
For the six months ended June 30, 2014, Trovagene Inc. (NASDAQ:TROV) on 7 August reported a net loss of $4.3 million, or $0.23 per share, as compared to a net loss of $6.4 million, or $0.41 per share, for the six months ended June 30, 2013.
Investors Are Watching: Digital River Inc. (NASDAQ:DRIV), Jazz ...
On 11 AUG Ocera Therapeutics, Inc. (NASDAQ:OCRX) posted its quarterly earnings results on Monday. The company reported ($0.46) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.45) by $0.01.
Top Wall Street Stories: Finisar Corp. (NASDAQ:FNSR), Microsoft Corporation ...
Ocera Therapeutics Inc. (NASDAQ:OCRX) last released its earnings data on Monday, August 11th. The company reported ($0.46) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.45) by $0.01.
Daily Digest
Novatel Wireless Inc.: Company was rated new "buy" at HC Wainwright & Co. LLC; the price target in $4. Ocera Therapeutics Inc.: Company announced the appointment of Steven P. James to its board of directors, serving as the lead independent director and ...
Stocks in News : National Beverage Corp. (NASDAQ:FIZZ), Points International ...
On 11 Aug 2014 Ocera Therapeutics, Inc. (Nasdaq:OCRX), a clinical stage biopharmaceutical company focused on acute and chronic orphan liver diseases, announced its financial results for the second quarter ended June 30, 2014.
Anacor Pharmaceuticals Appoints Wendell Wierenga to Its Board of Directors
In addition, Dr. Wierenga is a member of the boards of directors of XenoPort, Inc., Cytokinetics, Incorporated, Ocera Therapeutics, Inc., Apricus Biosciences, Inc. and Concert Pharmaceuticals, Inc. �The other members of the Board and I thank Paul for ...
Related articles »